<style face="normal" font="default" size="100%">Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in <em>KRAS-</em>mutated non-small cell lung cancer with <em>STK11</em>, <em>KEAP1,</em> or <em>TP53</em> comutations: subgroup results from the phase III IMpower150 trial</style>

Drupal-HighWire